Starting treatment with BEQALZI™

What is BEQALZI?

BEQALZI™ (sonrotoclax) is a prescription medicine used to treat adults with mantle cell lymphoma (MCL) that has come back or did not respond to previous treatment, and who have already received 2 treatments for their cancer, including a Bruton's tyrosine kinase (BTK) inhibitor. BEQALZI was approved based on patient response data. Studies are ongoing to confirm the clinical benefit of BEQALZI. It is not known if BEQALZI is safe and effective in children.

IMPORTANT SAFETY INFORMATION

BEQALZI can cause serious side effects, including:

- **Tumor Lysis Syndrome (TLS)**
  - TLS has occurred in patients treated with BEQALZI. TLS is caused by the fast breakdown of cancer cells, which can cause kidney failure, the need for dialysis treatment, and can be life-threatening. TLS can happen when you first start treatment, with dose increases, or if treatment is restarted.

Please see additional Important Safety Information throughout.

BEQALZI™ (sonrotoclax) tablets 1, 5, 20, 80 mg

Getting started on BEQALZI

BEQALZI offers a dosing schedule that includes a 4-week ramp-up which gradually increases to an ongoing daily dose beginning at Week 5.

- The 4-week ramp up period helps your body acclimate to the medication
- Before beginning treatment, it is important that you tell your healthcare provider about any medical conditions you have and all the medicines you take or plan to take, including any drugs, vitamins, minerals, natural supplements, or alternative medicines
- Tell your healthcare provider if you are pregnant, plan on becoming pregnant, or are breastfeeding

How to take BEQALZI



Take tablets with **a GLASS OF WATER DURING A MEAL**, once a day, at about the same time each day.



SWALLOW TABLETS WHOLE; do not break, chew, or crush.



KEEP TABLETS IN THE ORIGINAL STARTER PACKAGING for the first 4 weeks.

4-week ramp-up

- During the ramp-up you will take a single tablet on Days 1 to 3 of each week, increasing to 2 tablets on Days 4 to 7 of each week
- Your daily dose will gradually increase from 1 mg to 160 mg during these 4 weeks

Ongoing treatment

- After the 4-week ramp-up, the ongoing daily dose, 320 mg (four 80 mg tablets), begins on Day 1 of Week 5
- You will stay on this dose as long as it is helpful for you. Your healthcare provider will work with you to monitor your progress and help manage any side effects you may have

When taking BEQALZI



If a dose is missed in **LESS THAN 8 HOURS**, take dose with a meal as soon as possible and resume normal schedule.

If it has been **MORE THAN 8 HOURS**, do not take dose; resume normal schedule the following day.



DO NOT change your dose of BEQALZI or stop taking BEQALZI unless your healthcare provider tells you to.



If you vomit after taking BEQALZI, **DO NOT TAKE AN EXTRA DOSE**. Take the next dose at your usual time the next day.



DO NOT restart BEQALZI on your own if your healthcare provider has stopped treatment.



If you have questions regarding a missed dose, **SPEAK WITH YOUR HEALTHCARE PROVIDER**

Please see additional Important Safety Information throughout.

Possible side effects of BEQALZI

IF YOU ARE EXPERIENCING ANY SIDE EFFECTS, please contact your healthcare provider.

BEQALZI can cause serious side effects, including TLS, serious infections, and decreased white blood cell count (neutropenia).

The most common side effects of BEQALZI include pneumonia and tiredness.

The most common abnormal blood tests with BEQALZI are decreased white blood cell counts.

These are not all of the possible side effects of BEQALZI.

IMPORTANT SAFETY INFORMATION

- Before starting BEQALZI, your healthcare provider will assess your risk for TLS. You will receive other medicines and be advised to drink plenty of fluids during your treatment course. Some patients may need hospitalization for IV fluids and closer monitoring. Blood tests will be done before and during treatment. Keep all scheduled appointments.

Help reduce the risk of TLS

Tumor lysis syndrome (TLS) is a serious side effect caused by the fast breakdown of cancer cells which can cause kidney failure, the need for dialysis treatment, and can be life-threatening. The gradual dose ramp-up period is designed to help reduce this risk. It is important to follow the dosing schedule and stay hydrated throughout.



Drink 6 to 8 glasses (~51-68 oz) of water daily, starting 1 to 2 days before your first dose, on the day of your first dose, during dose increases, and if treatment is restarted. Ensure adequate hydration throughout treatment. Some patients may need hospitalization for intravenous (IV) fluids and closer monitoring.



Your healthcare provider will **prescribe medications before the first dose of BEQALZI to reduce the risk of TLS**. Your healthcare provider may suggest additional medications based on your TLS lab results.

You will have regular blood tests to check your tumor and kidney function.

Following the dosing schedule and hydration instructions is essential to help manage the risk of TLS.

IMPORTANT SAFETY INFORMATION

Before taking BEQALZI, tell your healthcare provider about all of your medical conditions, including if you have kidney problems, problems with body salts or electrolytes (such as potassium, phosphorus, or calcium), or a history of high uric acid or gout. Also tell your healthcare provider if you are pregnant, plan to become pregnant, or are breastfeeding or plan to breastfeed. BEQALZI may affect male and female fertility. If you receive BEQALZI while pregnant, it may harm your unborn baby.

Please see additional Important Safety Information throughout.

Please use the dosing calendar below as you begin BEQALZI

Dosing schedule for 4-week ramp-up phase

BEQALZI™ (sonrotoclax) tablets 1, 5, 20, 80 mg

Day of the week

	DAY 1	DAY 2	DAY 3	DAY 4	DAY 5	DAY 6	DAY 7
 WEEK 1	Take one 1 mg tablet	Take one 1 mg tablet	Take one 1 mg tablet	Take two 1 mg tablets together	Take two 1 mg tablets together	Take two 1 mg tablets together	Take two 1 mg tablets together
 WEEK 2	Take one 5 mg tablet	Take one 5 mg tablet	Take one 5 mg tablet	Take two 5 mg tablets together	Take two 5 mg tablets together	Take two 5 mg tablets together	Take two 5 mg tablets together
 WEEK 3	Take one 20 mg tablet	Take one 20 mg tablet	Take one 20 mg tablet	Take two 20 mg tablets together	Take two 20 mg tablets together	Take two 20 mg tablets together	Take two 20 mg tablets together
 WEEK 4	Take one 80 mg tablet	Take one 80 mg tablet	Take one 80 mg tablet	Take two 80 mg tablets together	Take two 80 mg tablets together	Take two 80 mg tablets together	Take two 80 mg tablets together

💧=Continue daily hydration 💧💧=Pay extra attention to hydration on these days



After the ramp-up, starting at Week 5, tablets will come as a 30-day supply in a pill bottle for your ongoing treatment.



IT IS IMPORTANT TO STAY HYDRATED.

Drink 6 to 8 glasses (~51–68 oz) of water daily, starting 1 to 2 days before you begin BEQALZI, on the day of your first dose, during dose increases, and if treatment is restarted.


Stay well hydrated throughout treatment, especially on dose increase days.

Use this page to write down any questions you may have for your doctor:

SCAN TO LEARN MORE ABOUT TAKING BEQALZI

myBeOneSupport®

We want you to focus on your treatment. To help meet your needs, myBeOne Support pairs you with a dedicated Oncology Nurse Advocate who can personalize support for you.



For any questions or to help you get started, simply call

1-833-234-4363

M–F, 8 AM to 8 PM ET,

to speak with an Oncology Nurse Advocate.

Or visit **myBeOneSupport.com**.

A myBeOne Support Oncology Nurse Advocate can help eligible patients with:

Simplifying access

- Assessment of insurance coverage
- Bridge supply during insurance coverage delays*
- Co-pay support for commercially insured patients*
- Free medication for uninsured and underinsured patients*

Education about BEQALZI

Along with your healthcare team, your Oncology Nurse Advocate can help answer questions you may have about treatment with BEQALZI.

Day-to-day living support

Living with cancer takes support. Your Oncology Nurse Advocate is well trained and dedicated to identifying independent organizations† that can help address your needs.

*Terms and conditions apply. Up to $25,000 per calendar year.

†Independent third-party organizations have their own rules for eligibility. BeOne Medicines has no involvement in their decision-making or eligibility criteria. This information is non-exhaustive and not meant as an endorsement from BeOne Medicines.

myBeOneSupport® is not insurance and does not guarantee product coverage or reimbursement.

IMPORTANT SAFETY INFORMATION

BEQALZI can cause serious side effects, including:

- **Tumor Lysis Syndrome (TLS)**
  - TLS has occurred in patients treated with BEQALZI. TLS is caused by the fast breakdown of cancer cells, which can cause kidney failure, the need for dialysis treatment, and can be life-threatening. TLS can happen when you first start treatment, with dose increases, or if treatment is restarted.
  - Before starting BEQALZI, your healthcare provider will assess your risk for TLS. You will receive other medicines and be advised to drink plenty of fluids during your treatment course. Some patients may need hospitalization for IV fluids and closer monitoring. Blood tests will be done before and during treatment. Keep all scheduled appointments.
  - Tell your healthcare provider right away if you develop symptoms such as nausea; vomiting; diarrhea; muscle cramps, weakness, or twitches; fatigue; decreased urination; swelling in your legs, ankles, or feet; numbness or tingling, especially around your mouth or in your hands and feet; confusion or difficulty staying alert; irregular or fast heart rate; or seizures.
  - Drink 6 to 8 glasses (about 1.5 to 2 liters or 51-68 ounces) of water each day starting 1 to 2 days before your first dose, on the day of your first dose, during dose increases, and if treatment is restarted.
- **Serious infections**. BEQALZI can cause death or serious infections. Your healthcare provider will monitor you for signs and symptoms of infection and treat you as needed. Tell your healthcare provider right away if you develop a fever or any signs of an infection.
- **Decreased white blood cell count (neutropenia)**, which can be serious or severe and increase the risk of infection. Your healthcare provider will check your blood counts during treatment and may decrease your dose, temporarily stop, or completely stop treatment if you get certain side effects.

Do not take BEQALZI with certain medicines called strong CYP3A inhibitors when starting treatment and while your dose is being increased because this may increase the risk of TLS. Other medicines, including moderate CYP3A inhibitors, may require dose changes. Tell your healthcare provider about all the medicines you take, and do not start new medicines during treatment without talking to your healthcare provider. Avoid grapefruit products, Seville oranges (often used in marmalades), and star fruit. These can increase the amount of BEQALZI in your blood.

BEQALZI™ (sonrotoclax) tablets 1, 5, 20, 80 mg

Before taking BEQALZI, tell your healthcare provider about all of your medical conditions, including if you have kidney problems, problems with body salts or electrolytes (such as potassium, phosphorus, or calcium), or a history of high uric acid or gout. Also tell your healthcare provider if you are pregnant, plan to become pregnant, or are breastfeeding or plan to breastfeed. BEQALZI may affect male and female fertility. If you receive BEQALZI while pregnant, it may harm your unborn baby. **If you are a female who can become pregnant**, your healthcare provider should do a pregnancy test before you start treatment and you should use effective birth control (contraception) during treatment and for 1 week after the last dose. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment and for 1 week after your last dose. Do not breastfeed during treatment and for 1 week after the last dose. **If you are a male with a female partner who can become pregnant**, use effective birth control (contraception) during treatment and for 1 week after the last dose.

The most common side effects of BEQALZI include pneumonia and tiredness. **The most common abnormal blood tests with BEQALZI are** decreased white blood cell counts.

If you have side effects, your healthcare provider may tell you to stop taking BEQALZI for a period of time. Do not restart BEQALZI on your own. Call your healthcare provider before you start taking BEQALZI again.

These are not all the possible side effects of BEQALZI. Call your healthcare provider for medical advice about side effects. You may report side effects to BeOne Medicines at 1-877-828-5596 or FDA at 1-800-FDA-1088 or **www.fda.gov/medwatch**.

Please see Medication Guide.

BeOne

BEQALZI, BeOne Medicines, and myBeOne Support are trademarks owned by BeOne Medicines I GmbH or its affiliates.
© BeOne Medicines I GmbH, 2026 All Rights Reserved.
1025-SON-PRC-003 08/2026